The Michelangelo trial revealed that adding atezolizumab to nab-paclitaxel and carboplatin did not improve 5-year event-free survival in patients with triple-negative breast cancer.
Kevin Kalinsky, MD, MS, of Glenn Family Breast Center, gives insight into the real-world data supporting the use of sacituzumab govitecan-hziy in the treatment of triple-negative breast cancer (TNBC).
Adding the CDK4/6 inhibitor to endocrine therapy among women with high-risk early breast cancer continues to show modest but clinically significant benefits 5 years in, compared with endocrine therapy alone.
Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, presented by The American Journal of Managed Care® in partnership with Emory's Winship Cancer Institute.